Sirona Dx is a CLIA accredited technical CRO, founded to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between life science tools developers and translational clinical research, our laboratory offers specialized high complexity single cell proteomics and genomics services to support biopharma drug discovery and development programs.
In contrast to most CROs, we embrace technologies at an early stage, often assisting life science
companies with product development. Our pharma clients benefit from early access to leading edge technologies along with the technical expertise to harness them. All of this within a CLIA accredited laboratory that supports pharma regulatory requirements.
Our team can assist with platform selection, assay design and optimization, validation and deployment of complex multi-analyte assays to accelerate therapies towards regulatory approval.
Harness breakthrough technologies to profile and integrate biology with single-cell resolution including tissue spatial context to reveal the next generation of precision biomarker signatures.
From exploratory testing and biomarker development through to clinical trials support, we partner with you every step of the way.
Depend on our capabilities and experience to advance your understanding of diseases and drugs at the molecular level using systems level single cell approaches.
Sirona Dx is committed to your success.
Dr.Nasry Yassa is an entrepreneurial executive with over 30 years of experience in clinical laboratories, contract research organizations, and pharmaceutical industries. Dr. Yassa Co-founded Sirona Dx Inc. a Contract Research Organization that offers specialized high complexity genomic services for platform technology firms and pharmaceutical companies.
Nasry spent the last 12 years of his career growing startup companies. At MolecularMD he was solely responsible for managing activities to commercialize the company's service portfolio. He directed staff of 60+ with scope breadth including infrastructure build, operation, business strategy and PMA submission. Prior to MolecularMD, he Co-founded Pathway Diagnostics and served as the Vice President of Operations where he managed a multi-disciplinary organization working to identify, develop, and in-license novel technology in a wide range of disease areas. At Specialty Lab, he was the Technical Director of the Development Department, directing the development of over 500 diagnostic in-house tests. At Hoffmann-La Roche, Nasry worked as a Research Scientist and then as a Product Support Manager working on the development of the first HIV Molecular Diagnostic test and on developing methods for reversible modification of thermo-stable enzymes (AmpliTaq® Gold). Prior to working at Hoffmann-La Roche, he worked at Bio-Rad laboratories as a Senior Production Manager of the HIV-1 P3 facility. At Ortho Diagnostic Sysytems Nasry worked as an Associate Scientist. Nasry started his career at Nichols Institute as a Manufacturing Chemist.
Nasry holds a B.S. in Medical Microbiology and Ph.D. in Bio-Chemistry.
Dr. Andrew Brown has over 20 years of sales and business development experience in the Life Science Tools industry, focused primarily on pharma/biotech and clinical lab market segments.
Before joining Sirona Dx, Andrew managed the proteomics business at Fluidigm leading adoption of mass cytometry and imaging mass cytometry systems.
At LifeTechnologies, Andrew executed a pioneering clinical market development strategy for Next Generation DNA Sequencing with the Ion Torrent Next Gen Sequencing platform.
As National Commercial Development Manager at Stratagene Andrew developed the North American pharma/biotech market with a focus on real time qPCR systems and applications.
Andrew has a PhD from the University of London / Imperial Cancer Research Fund, an MSc in Marine and Fisheries Science from the University of Aberdeen and a BSc in Microbiology from the University of London.
Dr. Bakker has held senior leadership positions in laboratory, pharmaceutical, and biotechnology industries. He has extensive expertise in the development, validation, and implementation of diagnostic assays and platform technologies and their application in clinical research. Andy’s understanding of GLP, GCP, and CLIA/CAP regulations has enabled him to set up several quality management systems in diverse operational settings. Bridging device and clinical drug development throughout his career, Dr, Bakker has been involved with over 1000 clinical trials. Before joining Sirona Dx, Dr. Bakker established the lab at Cynvenio Biosystems, as Vice President of Operations, he oversaw CLIA Operations and Clinical Trial Services. Dr. Bakker served as Vice President of Molecular Diagnostics and Clinical Trials at Solstas Lab Partners. At Amgen Inc., he developed a novel outsourcing and management organization as director of Technical Services that provides laboratory and imaging support to clinical studies worldwide. Prior to Amgen, Dr. Bakker was the vice president of clinical programs at Pathway Diagnostics where he established and managed the clinical trials organization. Before joining Pathway Diagnostics, Dr. Bakker directed several organizations at Specialty Laboratories (now Quest Diagnostics), including the genotyping laboratory, molecular technology development, and clinical trials. Dr. Bakker began his career as associate director of Long Beach Genetics, a leader in biological relationship, identity, and paternity analysis. Dr. Bakker received his Ph.D. from the University of California, Los Angeles and a B.S from the University of California, San Diego.
James Rader has over 20 years of experience in finance and accounting. As co-founder of a financial consulting company, Mr. Rader has worked with several companies as Chief Financial Officer. Mr. Rader was tasked with a variety of executive level finance activities including developing policies and procedures, recruiting staff into finance and accounting roles, sourcing outside financing and merger/acquisition activities. Prior to this, Mr. Rader served as an executive at several financial institutions including BNP Paribas and US Bancorp. Within the
banking industry, Mr. Rader managed a variety of teams focused on commercial finance, treasury services and product management. Mr. Rader holds a M.A. in Economics from University of Washington.
Dr. Mesa is a board certified pathologist and an Assistant Professor at the Department of Pathology, College of Osteopathic Medicine of the Pacific-Northewest, Western University of Health Sciences. He is also the founder and director of a leading surgical pathology reference lab service for ambulatory surgery centers (ASCs).
Dr. Mesa did his undergraduate studies at the University of North Texas, and medical school at the University of Osteopathic Medicine and Health Sciences in Des Moines, IA. He then did his Pathology Residency at the Cleveland Clinic, Mount Sinai Medical Center and Case Western Reserve University. Dr. Mesa is a member of the College of American Pathologists, the Oregon Pathologists Association, the Osteopathic Physicians and Surgeons of Oregon and the Catholic Medical Association.
Dr. Shahab Asgharzadeh is an Associate Professor of Pediatrics and Pathology at the University of Southern California and director of the Neuroblastoma Basic and Translational Program at CHLA. He specializes in treating children with neuroblastoma and medulloblastoma and leads a research laboratory aimed at understanding the role of the tumor microenvironment in biology of these tumors. His research also uses next generation sequencing technologies to discover novel targets for therapy. His group’s identification of the role of immune system in neuroblastomas has provided data for the use of new immunotherapeutic approaches in the treatment of this disease.
Dr. Asgharzadeh is a member of the NIH sponsored Neuroblastoma Therapeutically Applicable Research to Generate Effective Treatments (Neuroblastoma TARGET) project and an active member of the Children’s Oncology Group and serves on this organization’s Neuroblastoma Biology Committee.
A scientific leader with over 20 years of experience in delivering innovative solutions to support multiple aspects of clinical trials (early discovery, clinical development and diagnostics). Prior to joining Sirona Dx, Dr. Madan served as an Executive Director, Genomics at Covance Genomics Lab/LabCorp Clinical Trials, where he was responsible for all aspects of genomic activities at LabCorp Clinical Trials. At Covance, Anup played a key role in product development, evaluating new platforms and cultivating deep relationships with key opinion leaders in the field. Before joining Covance, Dr. Madan held the position of Senior Scientist, Co-Director Research, at Swedish Neuroscience Institute, Seattle. Prior to the Swedish Neuroscience Institute, he was an Assistant Professor at University of Iowa, Iowa City, IA. Dr. Madan started his career as Sr. Research Scientist at Institute for Systems Biology, Seattle, WA
Dr. Camille Troup has over 20 years of experience developing and commercializing biomolecular assays, platforms and workflows. Prior to joining SironaDx, she managed translational research projects across multiple platforms for clients at Core Diagnostics as a principal scientist. She is a co-inventor of the ViroSeq™ HIV genotyping assay developed at Applied Biosystems. As a Sr. Scientist at QuantaLife, she developed novel ddPCR applications and played a key role in the acquisition of QuantaLife by Bio-Rad, including supporting commercial adoption of ddPCR after the acquisition. As a senior field application scientist at Nanostring Technologies, she supported translational research programs for Pharma clients and CRO’s. She recently co-authored the biomarker study best practices white paper for the nCounter™ platform. She has a Ph.D. from the University of California San Francisco Department of Pharmaceutical Chemistry and a bachelor’s degree in biochemistry from the University of Minnesota.
Dr. Ken Pennline, obtained his PhD in Immunology from the Ohio State University in 1977. His professional experience began as a faculty member in the Department of Pathology, Georgetown University (5 years) before he joined Pharma as a Senior Principal Scientist and Director of Core Flow Cytometry for Schering Plough (12 years). Dr. Pennline then joined Esoterix in 1997 where he held several positions including Global Director of Operations in Oncology/Cell Analysis and Vice President of Scientific Affairs where he promoted the scientific capabilities in business development efforts globally. After the acquisition of Labcorp in 2005, he became Vice President of Sales and Marketing assuming the lead role for integrating and then managing the business development and marketing teams for the combined Clinical Trials organization from 2005-2009. In 2009 he was appointed to Vice President and Global Head of Laboratory Operations for LabCorp Clinical Trial Services. From 2011-2015 he held the position of Vice President and Global Head of Cytometry Services for the LabCorp Clinical Trial Services leading the advancement of this technology in novel drug development. Following the merger of LabCorp and Covance in 2015 he served as Executive Director and Global Head Cytometry Services for Covance Central Labs Services until May 2017.
Jon is an attorney and CPA who represents technology and emerging growth companies with respect to the formation, financing, governance, and transactional matters. He counsels clients on venture capital and angel financings, mergers and acquisitions, strategic alliances and joint ventures, technology licensing, commercial agreements and general business matters. Jon is experienced in stock option plans, executive compensation, corporate reorganizations and spinouts, securities offerings, and the formation of investment funds. Jon speaks frequently on the subjects of startups, financings, and mergers and acquisitions. Jon teaches an Entrepreneurship seminar at Lewis and Clark Law School. Prior to his legal career, Jon worked for four years for Arthur Andersen and Co., an international public accounting firm, as a financial statement auditor where he earned his certified public accounting license in 1989.